A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 Aug 2012 Results in the cohort of patients with extensive SCLC published in the Annals of Oncology.
- 13 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History